A Study of ES014 (Anti-CD39/TGF-β Bispecific Antibody) in Patients With Locally Advanced or Metastatic Solid Tumors

NCT05381935 · clinicaltrials.gov ↗

PHASE1

Phase

WITHDRAWN

Status

INDUSTRY

Sponsor class

Stopped Sponsor's clinical development strategy adjustment

Conditions

Advanced Solid Tumor

Interventions

DRUG: ES014
DRUG: ES014

Sponsor

Elpiscience Biopharma, Ltd.